Develops and commercializes therapies for diseases with unmet medical needs. Offers LUPKYNIS, a treatment for adult patients with active lupus nephritis. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 58% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $323.2M would still be left in the vault — a solid cushion for hard times.
The market pays 7.2× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
Against companies in its own sector, it looks cheaper than 73% of them.
Analysts' average target sits 1% below today's price.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades 51% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 58% a year on average.
There is $398.0M in the vault; even if every debt were paid off, $323.2M would remain.
Over the last 12 months, company executives reported 34 buys and 17 sells. Management buying with its own money is usually read as a good sign.
Our checks did not surface a specific risk to flag here. That is not the same as there being none.
On our five-subject report card, AUPH sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: AUPH is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.